Yeast-Based Platforms for Next-Generation Human Health Applications.

Yeast platforms are being redefined as programmable, scalable biomanufacturing factories and advanced living therapeutics for next-generation human health applications.

• Why it matters: Translational progress is needed to move yeast beyond traditional model roles and reduce technical barriers for clinical and industrial use.
• What they did: The review surveys conventional and non-conventional yeasts—Saccharomyces cerevisiae, Komagataella phaffii, Saccharomyces boulardii, and Yarrowia lipolytica—and highlights advances such as CRISPR-mediated multiplex editing, modular cloning, and high-throughput secretion screening.
• The result: It links these toolkits to applications including humanized N-glycosylation, AI-guided strain design, vaccine and enzyme production (e.g., HBV, HPV, ecallantide), and emerging gut-adapted LBPs for in situ delivery and biosensing.

AI summary of the abstract · may contain errors · not medical advice · read the paper.